Clinical trial
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or…
NCT00096486 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00096486 |
|---|---|
| Title | Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer |
| Official title | A Phase I/II Trial of Fixed Doses of Daily Gefitinib With Escalating Doses of Daily RAD001 in Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | everolimus, gefitinib |
| Enrollment | 74 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Nov 10, 2004 |
| Last update posted | Jan 21, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: